Sixteen departments in China's Shandong province, led by the Health Commission, issued the Work Plan for Accelerating Clinical Translation and Application Innovation of Brain-Computer Interfaces, document number Lu Wei Yi Zi [2026] No. 13, dated July 7, 2026 and released on July 8. It is the only provincial BCI document led by a health authority and Shandong's second after the science department's industry plan. The plan advances a positioning it summarises as validated in Shandong, applied globally, working through an alliance, scenarios, policy and industry follow-through. Targets rise in four steps: an operating clinical research alliance in 2026; about 20 core technology breakthroughs and 30 technology SMEs by 2027; at least 30 alliance members, more than 20 foreign and domestic teams setting up validation bases, more than 30 multicentre projects and a 2 billion yuan industry by 2028; and a national validation cluster by 2030.
Why it matters
The only provincial BCI document led by a health commission, aimed squarely at the clinical evidence bottleneck. The framing of validation in Shandong for global application is unusual: the province is trying to occupy one link of the value chain through patient volume and trial capacity rather than manufacturing. It also carries industrial targets, including a 2 billion yuan sector by 2028, so it is not a purely clinical plan.